Annals of Hematology

, Volume 97, Issue 9, pp 1695–1700 | Cite as

Ethnicity-specific impact of HLA I/II genotypes on the risk of inhibitor development: data from Korean patients with severe hemophilia A

  • Hyun-Young Kim
  • Jin-Hee Cho
  • Hee-Jung Kim
  • Hae-Sun Chung
  • Sun-Hee Kim
  • Ki-O Lee
  • Soo-Young Jung
  • Ki-Young YooEmail author
  • Hee-Jin KimEmail author
Original Article


Inhibitor development is the most serious complication in patients with hemophilia. We investigated association of HLA genotypes with inhibitor development in Korean patients with severe hemophilia A (HA). HLA genotyping was done in 100 patients with severe HA including 27 patients with inhibitors. The allele frequencies between inhibitor-positive and inhibitor-negative patients were compared. HLA class I alleles were not associated with the inhibitor status. In HLA class II, DRB1*15 [n = 100, odds ratio (OR) 0.217, P = 0.028] and DPB1*05:01 [OR 0.461, P = 0.026] were negatively associated with inhibitor development. In a subgroup of patients with intron 22 inversion, C*07:02 was positively associated with inhibitor development [n = 30, OR 5.500, P = 0.043]. In the subgroup of patients without intron 22 inversion, the negative association between DPB1*05:01 and inhibitor development was reinforced [n = 70, OR 0.327, P = 0.010], and positive association of DRB1*13:02 and DPB1*04:01 with inhibitor development was identified [OR 3.059, P = 0.037 for both]. Previously reported risk alleles were not consistently associated with inhibitor risk in our series. This study demonstrated the profile of HLA alleles associated with inhibitor risk in Korean patients with severe HA was different from that in patients of other ethnicities, which needs to be considered in risk assessment and management.


Hemophilia A Inhibitor HLA genotypes Mutation Korea 


Funding information

This study was supported by a grant from the Korea Food & Drug Administration (KFDA) and by a grant from Korea Hemophilia Foundation.

Compliance with ethical standards

This study was approved by the Institutional Review Board of Samsung Medical Center (Seoul, Korea), and all patients gave written informed consent in accordance with the Declaration of Helsinki.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

277_2018_3358_MOESM1_ESM.docx (44 kb)
ESM 1 (DOCX 44 kb)


  1. 1.
    Klinge J, Ananyeva NM, Hauser CA, Saenko EL (2002) Hemophilia A—from basic science to clinical practice. Semin Thromb Hemost 28:309–322. CrossRefPubMedGoogle Scholar
  2. 2.
    Ryu JE, Park YS, Yoo KY, Lee KD, Choi YM (2015) Immune tolerance induction in patients with severe hemophilia A with inhibitors. Blood Res 50:248–253. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Chalmers EA, Brown SA, Keeling D, Liesner R, Richards M, Stirling D, Thomas A, Vidler V, Williams MD, Young D (2007) Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 13:149–155. CrossRefPubMedGoogle Scholar
  4. 4.
    Astermark J, Oldenburg J, Escobar M, White GC 2nd, Berntorp E (2005) The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 90:924–931PubMedGoogle Scholar
  5. 5.
    Gouw SC, van den Berg HM, Oldenburg J, Astermark J, de Groot PG, Margaglione M, Thompson AR, van Heerde W, Boekhorst J, Miller CH, le Cessie S, van der Bom JG (2012) F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 119:2922–2934. CrossRefPubMedGoogle Scholar
  6. 6.
    Pandey GS, Yanover C, Miller-Jenkins LM, Garfield S, Cole SA, Curran JE, Moses EK, Rydz N, Simhadri V, Kimchi-Sarfaty C, Lillicrap D, Viel KR, Przytycka TM, Pierce GF, Howard TE, Sauna ZE, Investigators PS (2013) Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. Nat Med 19:1318–1324. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Gouw SC, van den Berg HM (2009) The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 35:723–734. CrossRefPubMedGoogle Scholar
  8. 8.
    Hay CR, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FG, Preston FE, Peake IR (1997) HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 77:234–237CrossRefPubMedGoogle Scholar
  9. 9.
    Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E (1997) HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 77:238–242CrossRefPubMedGoogle Scholar
  10. 10.
    Pavlova A, Delev D, Lacroix-Desmazes S, Schwaab R, Mende M, Fimmers R, Astermark J, Oldenburg J (2009) Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 7:2006–2015. CrossRefPubMedGoogle Scholar
  11. 11.
    Ragni MV, Ojeifo O, Feng J, Yan J, Hill KA, Sommer SS, Trucco MN, Brambilla DJ (2009) Risk factors for inhibitor formation in haemophilia: a prevalent case-control study. Haemophilia 15:1074–1082. CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, Lefvert AK (2006) Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 108:3739–3745. CrossRefPubMedGoogle Scholar
  13. 13.
    Kim HJ, Chung HS, Kim SK, Yoo KY, Jung SY, Park IA, Lee KO, Kim SH, Kim HJ (2012) Mutation spectrum and inhibitor risk in 100 Korean patients with severe haemophilia A. Haemophilia 18:1008–1013. CrossRefPubMedGoogle Scholar
  14. 14.
    Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E (1995) The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 73:247–251CrossRefPubMedGoogle Scholar
  15. 15.
    Liu Q, Sommer SS (1998) Subcycling-PCR for multiplex long-distance amplification of regions with high and low GC content: application to the inversion hotspot in the factor VIII gene. BioTechniques 25:1022–1028PubMedCrossRefGoogle Scholar
  16. 16.
    Bagnall RD, Waseem N, Green PM, Giannelli F (2002) Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood 99:168–174CrossRefPubMedGoogle Scholar
  17. 17.
    Ohta H, Takahashi I, Kojima T, Takamatsu J, Shima M, Yoshioka A, Saito H, Kamiya T (1999) Histocompatibility antigens and alleles in Japanese haemophilia A patients with or without factor VIII antibodies. Tissue Antigens 54:91–97CrossRefPubMedGoogle Scholar
  18. 18.
    Wieland I, Wermes C, Eifrig B, Holstein K, Pollmann H, Siegmund B, Bidlingmaier C, Kurnik K, Nimtz-Talaska A, Niekrens C, Eisert R, Tiede A, Ebenebe C, Lakomek M, Hoy L, Welte K, Sykora KW (2008) Inhibitor-Immunology-Study. Different HLA-types seem to be involved in the inhibitor development in haemophilia A. Hamostaseologie 28(Suppl 1):S26–S28PubMedGoogle Scholar
  19. 19.
    De Barros MF, Herrero JC, Sell AM, De Melo FC, Braga MA, Pelissari CB, Machado J, De Souza Schiller S, De Souza Hirle L, Visentainer JE (2012) Influence of class I and II HLA alleles on inhibitor development in severe haemophilia A patients from the south of Brazil. Haemophilia 18:e236–e240. CrossRefPubMedGoogle Scholar
  20. 20.
    Pergantou H, Varela I, Moraloglou O, Economou M, Spanou K, Kapsimali Z, Constantinidou N, Platokouki H (2013) Impact of HLA alleles and cytokine polymorphisms on inhibitors development in children with severe haemophilia A. Haemophilia 19:706–710. CrossRefPubMedGoogle Scholar
  21. 21.
    Lacroix-Desmazes S, Navarrete AM, Andre S, Bayry J, Kaveri SV, Dasgupta S (2008) Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 112:240–249. CrossRefPubMedGoogle Scholar
  22. 22.
    Lamberth K, Reedtz-Runge SL, Simon J, Klementyeva K, Pandey GS, Padkjaer SB, Pascal V, Leon IR, Gudme CN, Buus S, Sauna ZE (2017) Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools. Sci Transl Med 9:eaag1286. CrossRefPubMedGoogle Scholar
  23. 23.
    Pashov AD, Calvez T, Gilardin L, Maillere B, Repesse Y, Oldenburg J, Pavlova A, Kaveri SV, Lacroix-Desmazes S (2014) In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. Haemophilia 20:176–184. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Hyun-Young Kim
    • 1
    • 2
  • Jin-Hee Cho
    • 1
  • Hee-Jung Kim
    • 1
    • 3
  • Hae-Sun Chung
    • 1
    • 4
  • Sun-Hee Kim
    • 1
  • Ki-O Lee
    • 5
  • Soo-Young Jung
    • 6
  • Ki-Young Yoo
    • 6
    Email author
  • Hee-Jin Kim
    • 1
    Email author
  1. 1.Department of Laboratory Medicine & Genetics, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulSouth Korea
  2. 2.Department of Laboratory Medicine, Gyeongsang National University HospitalGyeongsang National University School of MedicineJinjuSouth Korea
  3. 3.Department of Laboratory Medicine, CHA Gangnam Medical CenterCHA University School of MedicineSeoulSouth Korea
  4. 4.Department of Laboratory MedicineEwha Womans University College of MedicineSeoulSouth Korea
  5. 5.Samsung Biomedical Research InstituteSamsung Medical CenterSeoulSouth Korea
  6. 6.Korea Hemophilia FoundationSeoulSouth Korea

Personalised recommendations